Evidence map›Paper›PMID 29148252›Full record

ArticleCancer medicine2018

Sex hormone-binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer.

Chao-Wen Cheng, Che-Chang Chang, Yudha Nur Patria, Ruei-Ting Chang, Yun-Ru Liu, Fu-An Li, Hsiu-Ming Shih, Ching-Yu Lin

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Circulating Proteins as Diagnostic Markers in Gastric Cancer.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Chao-Wen ChengGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.
Che-Chang ChangGraduate Institute of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.ORCID 0000-0001-8080-2094
Yudha Nur PatriaGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.
Ruei-Ting ChangGraduate Institute of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.
Yun-Ru LiuJoint Biobank, Office of Human Research, Taipei Medical University, Taipei, 11031, Taiwan.
Fu-An LiInstitute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan.
Hsiu-Ming ShihGraduate Institute of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.
Ching-Yu LinSchool of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.
Taipei Medical University · TWInstitute of Biomedical Sciences, Academia Sinica · TWTaipei Medical University Hospital · TWUniversitas Gadjah Mada · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of blood plasma biomarkers in gastric cancer (GC) management is limited due to a lack of reliable biomarkers. An LC-MS/MS assay and a bioinformatic analysis were performed to identify blood plasma biomarkers in a GC discovery cohort. The data obtained were verified and validated by western blotting and an ELISA in an independent study cohort. A label-free quantification analysis of the MS data using PEAKS7 software found that four plasma proteins of apolipoprotein C-1, gelsolin, sex hormone-binding globulin (SHBG), and complement component C4-A were significantly overexpressed in GC patients. A western blot assay of these plasma proteins showed that only SHBG was consistently overexpressed in the patient group. ELISA measurement of SHBG blood plasma levels confirmed that the patient group had significantly higher SHBG levels than the control group. SHBG levels in the patient group remained significantly higher after being stratified by gender, age, and disease stage. These findings show that LC-MS/MS is powerful and highly sensitive for plasma biomarker discovery, and SHBG could be a potential plasma biomarker for GC management.

Indexed as

AdultAgedBiomarkersBiomarkers, TumorBlotting, WesternCase-Control StudiesChromatography, High Pressure LiquidEarly Detection of CancerEnzyme-Linked Immunosorbent AssayFemaleHealthy VolunteersHumansMaleMiddle AgedSex Hormone-Binding GlobulinStomach NeoplasmsBiomarkersBiomarkers, TumorSex Hormone-Binding GlobulinSHBG protein, humanGastric cancerLC-MS/MSmass spectrometryproteomicsSHBG

Identifiers

PMID29148252
PMCPMC5773940
OpenAlexW2769052438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.